Phase 2Completed
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
Multicenter, Double Blind, Metronidazole Controlled, Dose Range Finding Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
- Sponsor
- Romark Laboratories L.C. (Industry)
- Enrollment
- 114 planned
- Conditions
- Clostridium Difficile
- Interventions
- Nitazoxanide; Metronidazole
- Ages
- adults, older adults
- Registry
- NCT00417872
Full record on ClinicalTrials.gov
From the registry
The primary objective is to demonstrate non-inferiority of nitazoxanide administered 500 mg b.i.d compared to metronidazole administered 250 mg q.i.d. in resolving symptoms of Clotridium difficile colitis after seven days of treatment. Secondary objectives are to provide information on the times from first dose to last unformed stool and resolution of symptoms of colitis, the sustained response rates for the different tratment groups and the effect of treatment on Clostridium difficile toxin enzyme immunoassay/culture results during hospitalization.
Primary outcomes
- Clinical response (resolution of all symptoms present at baseline) recorded on day 8
History
Registered
Study completion
Started